FARAH CHAMPSI

Farah Champsi stands as a distinguished Managing Partner at InterWest Partners, a prominent venture capital firm known for its strategic investments in groundbreaking companies. At InterWest, Ms. Champsi spearheads the firm's robust healthcare investment practice, bringing her extensive expertise to bear on a diverse portfolio of innovative medical enterprises. Her primary investment focus areas include medical devices, diagnostics, and specialty pharmaceuticals, where she actively seeks out companies developing transformative solutions to address critical healthcare needs.

Ms. Champsi's career trajectory is marked by a profound commitment to the healthcare sector and a strong foundation in finance. Before joining InterWest Partners in 2000, she honed her strategic acumen at McKinsey & Company, where she was an integral part of their healthcare practice. This experience provided her with invaluable insights into the operational and market dynamics of the medical industry. Prior to McKinsey, Ms. Champsi gained hands-on experience in the pharmaceutical world at Genentech, contributing to their marketing and sales efforts. Her early career also included a significant tenure in investment banking at Morgan Stanley, equipping her with a solid understanding of financial markets and corporate strategy. Academically, Ms. Champsi holds an MBA from Stanford University's Graduate School of Business and a Bachelor of Arts degree from Yale University, further solidifying her analytical and leadership capabilities.

Throughout her tenure at InterWest Partners, Farah Champsi has been instrumental in identifying and nurturing numerous successful ventures. Her impressive portfolio of investments and board directorships showcases her keen eye for innovation and market potential. Notable past and present board roles and investments include AcelRx Pharmaceuticals (ACRX), BioMimetic Therapeutics (acquired by Wright Medical), Cardiva Medical (acquired by Haemonetics), Corcept Therapeutics (CORT), Epizyme (acquired by Ipsen), Inspire Medical Systems (INSP), KAI Pharmaceuticals (acquired by Amgen), Labrys Biologics (acquired by Celgene), Lumena Pharmaceuticals (acquired by Shire), Portola Pharmaceuticals (acquired by Alexion), Proteolix (acquired by Onyx Pharmaceuticals), Spinal Kinetics (acquired by Johnson & Johnson), and Xenon Pharmaceuticals (XENE). These investments span a wide range of therapeutic areas and technological advancements, underscoring her versatile approach to healthcare innovation.

Farah Champsi's leadership at InterWest Partners is characterized by her ability to combine deep industry knowledge with strategic financial insight. She is a trusted advisor to the companies she invests in, providing guidance that helps them navigate complex regulatory landscapes, accelerate product development, and achieve commercial success. Her dedication to fostering innovation in healthcare continues to drive significant advancements and deliver strong returns for InterWest Partners and its stakeholders.